Abstract
Prostate Cancer (PCa) is characterized by slow growth and represents a type of androgen dependent neoplasia. The Androgen Receptor (AR) plays a key ro le in prostate carcinogenesis and metastasis. Thus, Androgen Deprivation Therapies (ADT) are often used to treat PCa. However, at the time when PCa acquired castration-resistant phenotype (CPRC), ADT is no longer effective. In fact, it is n…